02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring...
23:41 , Apr 26, 2018 |  BC Innovations  |  Product R&D

Brake for gas

Elpiscience Biopharmaceuticals Co. Ltd. has emerged from stealth mode with an unconventional bispecific that simultaneously removes the brakes and steps on the gas for antitumor immunity, but only inside tumors. The goal is to upstage...
20:40 , Sep 8, 2017 |  BC Week In Review  |  Company News

Aptevo regains rights to MOR209/ES414 from MorphoSys

Aptevo Therapeutics Inc. (NASDAQ:APVO) said it ended a 2014 deal with MorphoSys AG (Xetra:MOR; Pink:MPSYY) granting the German company worldwide rights to APVO414 (formerly MOR209/ES414). Aptevo plans to continue to develop the bispecific ADAPTIR molecule...
07:00 , Oct 24, 2016 |  BioCentury  |  Emerging Company Profile

RORing against resistance

  Oncternal Therapeutics Inc.’s ROR1 inhibitor could be combined with BTK inhibitors to increase response rates in chemotherapy-resistant or refractory hematologic cancers such as chronic lymphocytic leukemia and mantle cell lymphoma. The Bruton’s tyrosine kinase...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Company News

Emergent BioSolutions, Aptevo deal

Biodefense company Emergent completed its spin out of newco Aptevo, which will house Emergent’s oncology and hematology assets. Aptevo’s marketed products include hemophilia drug Ixinity trenonacog alfa. Its pipeline includes Emergent’s ADAPTIR platform, including bispecific...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Financial News

Aptevo completes debt financing

Aptevo Therapeutics Inc. (NASDAQ:APVO), Seattle, Wash.   Business: Cancer, Hematology, Autoimmune   Date completed: 2016-08-04   Type: Debt financing   Raised: $20 million   Investor: MidCap Financial   Note: Aptevo drew down $20 million in...
02:09 , Jan 22, 2016 |  BC Extra  |  Company News

Management tracks

Oncology company Affimed N.V. (NASDAQ:AFMD) named Joerg Windisch COO. Windisch was CSO at the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN). Emergent BioSolutions Inc. (NYSE:EBS) named a management team for planned oncology and hematology spinout...